|Afexa Announces Results Of Clinical Trial Of Dilexaponan. Celgene Announces Additional Share Repurchase Authorization.|
|By Staff and Wire Reports|
|Thursday, 18 August 2011 18:55|
Afexa Life Sciences Inc. (OTC:AFXSF) announced promising results of a pilot clinical study investigating the effects of a new formulation, Dilexaponan (LIP-01) on cholesterol management. Dilexaponan is a polymolecular formulation isolated from botanical sources and developed and standardized using ChemBioPrint technology.
This open label and proof of concept study explored the safety and optimum dosing range for Dilexaponan in 39 patients with elevated total cholesterol levels. The study was led by principal investigator Dr. Richard Lewanczuk, Professor, Endocrinology and Metabolism, University of Alberta, in collaboration with Dr. Jay Udani, Assistant Clinical Professor, UCLA, CEO, Medicus Research LLC.
The results, awaiting final peer review, demonstrated that patients taking Dilexaponan had favourable changes in multiple cholesterol measures. All Dilexaponan doses tested (0.333, 1, and 2 g/day) were equally effective in significantly reducing low-density lipoprotein (LDL) cholesterol after a two month treatment duration versus baseline (pless than 0.05).
There were also significant and positive time-dependent decreases in the ratio of total cholesterol to high-density lipoprotein (HDL) cholesterol, and ratio of LDL cholesterol to HDL cholesterol compared to baseline (pless than 0.05) for each dose tested. Dilexaponan was generally well tolerated.
Celgene Corporation (NASDAQ:CELG) announced the Company’s Board of Directors has authorized the repurchase of up to an additional $2 billion of the Company’s common stock.
This open-ended program is effective immediately. Purchases may be made in the open market or in privately negotiated transactions from time to time, as determined by Celgene’s management and in accordance with the requirements of the Securities and Exchange Commission.
Amgen (NASDAQ:AMGN) today announced that it will present data from several Prolia® (denosumab) studies, including eight year efficacy and safety data from a Phase 2 extension study in women with postmenopausal osteoporosis with low bone mineral density (BMD), at the 2011 American Society for Bone and Mineral Research (ASBMR) Annual Meeting in San Diego, Calif. from Sept. 16-20, 2011.
Cardium Therapeutics (NYSE Amex:CXM) today reported that it had received funds corresponding to the final $1.1 million payment from Royal Philips Electronics in connection with Philips' acquisition of Innercool Therapies from Cardium.
Celsion Corporation (NASDAQ: CLSN), a leading oncology drug development company, announced today that the New Jersey Economic Development Authority has approved the Company's application for a Business Employment Incentive Program (BEIP) grant. BEIP grants are available to economically viable expanding or relocating businesses that create jobs in New Jersey.
Cell Therapeutics, Inc. (NASDAQ:CTIC and MTA: CTIC) announced that enrollment has opened for a randomized phase II clinical study comparing the combination of OPAXIO (paclitaxel poliglumex, PPX) and radiation ("RT") to the combination of temozolomide ("TMZ") and RT for patients with newly diagnosed glioblastoma, a high-grade malignant brain tumor.
Digirad Corporation (NASDAQ: DRAD) today announced that management is scheduled to make an investor presentation at the 2011 Southern California Investor Conference on Monday, August 29, at 9:00 am Pacific Time.
Graymark Healthcare, Inc. (NASDAQ: GRMH), the nation's second largest provider of diagnostic sleep services and an innovator in comprehensive care for obstructive sleep apnea (OSA), has been invited to present at the Midwest IDEAS Investor Conference.
Micro Imaging Technology, Inc. (OTCBB: MMTC) (OTCQB: MMTC) announced on July 26, 2011 that it has entered into a significant long-term equity alliance with EPIC Corporation (OTC: EPOR).
SeraCare Life Sciences (NASDAQ:SRLS), a global life sciences company providing vital products and services to facilitate the discovery, development and production of human diagnostics and therapeutics, today announced that the Company has introduced three new, differentiated panels to its product portfolio -- an HIV/HCV/HBV Nucleic Acid Qualification Panel, an HIV-1 RNA Linearity Panel and an Anti-HIV-2 Performance Panel.
TheDirectory.com, Inc. (PINKSHEETS: SEEK) today announced that it will host an investor conference call after the market close at 4:15 EDT.